Roundtable Discussion: Bridging Innovation & Commercialisation to Overcome Barriers in Novel Obesity Modalities
- Transitioning from preclinical neuronal and mitochondrial targets to clinical development to diversify mechanisms and reduce reliance on incretins
- Optimise delivery methods to enhance precision and durability of therapies and lower long-term costs
- Designing adaptive trials for GIPR- and DNA-based therapies to mitigate risks in heterogenous patient populations and accelerate regulatory approval